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Abstract
MicroRNAs (miRNAs) are small, non-coding RNA molecules which are emerging as key regulators of numerous cellular
processes. Compelling evidence links miRNAs to the control of neuronal development and differentiation, however, little is
known about their role in neurodegeneration. We used microarrays and RT-PCR to profile miRNA expression changes in the
brains of mice infected with mouse-adapted scrapie. We determined 15 miRNAs were de-regulated during the disease
processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and
miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown
to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved,
disease-specific pattern of differentially expressed miRNAs is associated with prion–induced neurodegeneration.
Computational analysis predicted numerous potential gene targets of these miRNAs, including 119 genes previously
determined to be also de-regulated in mouse scrapie. We used a co-ordinated approach to integrate miRNA and mRNA
profiling, bioinformatic predictions and biochemical validation to determine miRNA regulated processes and genes
potentially involved in disease progression. In particular, a correlation between miRNA expression and putative gene targets
involved in intracellular protein-degradation pathways and signaling pathways related to cell death, synapse function and
neurogenesis was identified.
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Introduction
Transmissible spongiform encephalopathies (TSEs), or prion
diseases, are an invariably fatal class of neurodegenerative
disorders. Substantial evidence links the development of disease
with the conformational conversion of PrP
C, a normal cellular
protein, into PrP
Sc, a structural isoform that is infectious [1]. In
contrast, very little is known about the molecular pathways
triggered by these agents that lead to the damage, and ultimate
death of neurons. Molecular events leading to prion induced
neurodegeneration are poorly characterized and this is an
important field of ongoing research, potentially leading to the
development of treatments. Efforts have been made to identify the
genes involved in pathogenesis at various stages of the disease in
both in vivo and in vitro models by microarray analysis of brain
tissue [2–6]. Specific in vitro models have looked at the involvement
of genes expressed in a number of different CNS cell types
including neuronal cells [7–9], microglial cells [10,11] and
astrocytes [12]. While it is useful to determine all those genes
that are potentially involved in the disease process it is especially
important for us to identify the key regulators of these processes;
especially the pathways that lead to death in neurons. These may
include transcription factors and regulatory protein kinases.
The recent identification of microRNAs (miRNAs) has revealed
an important layer of post-transcriptional gene regulation.
MiRNAs are a class of small (,18–25 nucleotides long),
endogenous, non-coding RNA molecules that post-transcription-
ally regulate protein coding mRNA in both plants and animals.
Several hundred miRNAs have been identified, many of which are
tissue-specific and/or temporally regulated in their expression
[13]. The biological function of only a small fraction of these
miRNAs have been reported in detail and point to their
involvement in a variety of developmental and physiological
processes. MiRNAs mediate gene silencing by binding to specific
target sites within the 39UTR of mRNA to either block translation
or to bring about degradation of transcripts. These effects can be
subtle and in a number of instances result in ‘fine-tuning’ of gene
expression [14,15]. Among vertebrate miRNAs, where the
complementarity between the miRNA and its target site on the
mRNA is imperfect, there exists the possibility for each miRNA to
regulate hundreds of potential targets. Unexpectedly, recent work
has shown miRNAs to be involved in the activation of gene
expression in certain conditions such as cellular stress [16,17].
Aberrant miRNA expression patterns have been described in
several diseases including neurodegenerative diseases [18–21].
Furthermore, using Purkinje cells as a model system to analyze the
role of miRNAs in postmitotic, differentiated neurons, the
inactivation of Dicer enzyme leads to rapid loss of cell-specific
miRNAs and the slow degeneration of the Purkinje cells leading to
ataxia and severe cerebellar dysfunction, suggesting miRNAs are
required to maintain neuronal integrity [22].
Here we present the first comprehensive analysis of miRNA
expression in the brain during prion-induced neurodegeneration.
We report the differential expression of 15 miRNAs, the majority
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3652of which are up-regulated during prion disease. Using miRNA
target prediction programs in combination with mRNA profiling
we have identified pathways and networks of genes in which
miRNA regulation is potentially important during mouse scrapie.
Results
De-regulation of miRNA expression during prion disease
in mice
To determine whether the expression profile of miRNAs
changes during prion disease, we analyzed the global expression
of mature miRNAs in the brains of mice intra-cerebrally
inoculated with scrapie strain 22A (n=6). We used a custom, in-
house manufactured miRNA microarray platform to profile the
expression of miRNAs [23]. In total, we determined differential
expression of 14 miRNAs in the brains of scrapie infected versus
mock-infected mice using this microarray. In some cases, the
differential signal was identified by multiple probes on the array
which were designed to identify species specific miRNA sequences,
some of which differ by one or two nucleotides from the mouse
sequence. We used qRT-PCR (TaqManH miRNA Assays) to
validate the expression of these 14 miRNAs, 8 up-regulated and 6
down-regulated. Our criteria for TaqManH validation was that at
least 5 of the 6 infected mice showed a mean fold change .1.75.
Using this criteria we were able to confirm the expression levels of
7/8 up-regulated miRNAs and 1/6 down-regulated miRNAs,
shown in Table 1.
We have previously found that TaqManH miRNA Assays are
more sensitive for detection of low abundance miRNAs than our
custom microarray [23]. We therefore screened a further 157
miRNAs for differential expression using the TaqManH panel. We
determined that 114 of these miRNAs were present at detectable
levels in mouse brain and that a further 6 up-regulated miRNAs
and 1 down-regulated miRNA that adhered to our criteria (Data
S1). These disease-associated miRNAs are also listed in Table 1. In
addition, we detected a trend in the up-regulation of the following
miRNAs, although the values were not consistent enough to meet
the criteria that 5 of the 6 infected mice show a fold change .1.75;
miR-200a, miR-200b, miR-26a, miR-186, miR-331-3p, miR-152,
miR-221. Included as annotation in Table 1 is the relative
abundance of each miRNA in normal CNS tissues, as measured
by qRT-PCR [23]. The de-regulated miRNAs exhibit a full range
of expression levels in normal CNS tissue from miRNAs found at
very low abundance in the brain, such as miR-203 which is
preferentially expressed in endothelial cells, to highly expressed
miRNAs such as let-7b and let-7d.
Computational predictions of the putative targets of de-
regulated miRNAs
A single vertebrate miRNA can target hundreds of mRNA
transcripts for either translation repression or degradation [24,25].
We used the computational algorithms miRanda, PicTar, and
TargetScan to identify prion-related potential target genes of the
de-regulated miRNAs based on seed-sequence homology with 39
UTRs of mRNA transcripts [26–28]. We relied on a consensus-
based approach by considering only those target genes that were
similarly predicted by two or more of these algorithms. The total
number of target genes predicted for the differentially expressed
miRNAs by two or more of the leading target finding algorithms
was 1282, which are listed in Data S2. Of these, 753 are annotated
in the Ingenuity Pathway Analysis (IPA) database in terms of their
biological function. The most enriched functional groups of genes
amongst the miRNA targets, and the canonical pathways within
which they play a role, are provided in Figure 1. Putative target
genes include many previously reported to play a role in various
Table 1. MiRNAs identified as differentially expressed in CNS tissues of scrapie infected mice.
Average fold Change by TaqManH
miRNA Assay Identified by miRNA Microarray Probes
miRNA abundance in brain tissues
(qRT-PCR)
*
Mouse Human Rat
Up-regulated
miR-342-3p 3.3 NN N +++
miR-320 2.9 NN ++
miR-let-7b 2.7 NN N ++++
miR-328 2.7 NN N +++
miR-191 2.0 NN N +++
miR-let-7d 1.9 NN N ++++
miR-370 1.9 NN +
miR-128 3.0 ++
miR-139-5p 3.0 +
miR-146a 2.6 ++
miR-339-5p 2.3 +
miR-203 2.1 +
miR-181a-1* 1.9 +
Down-regulated
miR-338-3p 26.5 NN N ++
miR-337-3p 23.1 +
MiRNAs which exhibit a trend towards up-regulation; miR-200a, miR-200b, miR-26a, miR-186, miR-331-3p, miR-152, miR-221.
*Results from [23].
doi:10.1371/journal.pone.0003652.t001
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accumulation of aggregated proteins. MiRNAs have already been
shown to play a role, possibly positively influencing neuronal
survival, in the modulation of Ataxin-3 (ATXN3) in the
polyglutamine disease spinocerebellar ataxia type 3 (SCA3) where
the miRNA ban was determined to act down-stream of ATXN-3
toxicity [18]. Bioinformatic analysis identified Ataxin-1 (ATXN1)
itself as a potential target of miRNAs up-regulated in this study.
The disruption in the clearance of protein aggregates by the
ubiquitin-proteasome (UPS) pathway has also been found to play a
role in pathogenesis of several neurodegenerative conditions
including late-onset Parkinson’s and Huntington’s disease [29].
Over 30 genes involved in the UPS pathway are potential targets
of the de-regulated miRNAs we have identified. These include
ubiquitin, ubiquitin-conjugating enzymes and the ubiquitin
protein ligase NEDD4; also amongst the targets are genes involved
in the unfolded-protein response, valosin-containing protein, VCP
(CDC48/p97), which is important for the shuttling of ubiquiti-
nated proteins from the endoplasmic reticulum (ER) to the
proteasome, and the transcription factor X-box binding protein 1,
XBP1, activated following the accumulation of unfolded proteins
in the ER. A biological network generated by the Ingenuity
Pathway Analysis tool (IPA) is provided in Figure 2 which shows
the high degree of interactions between the potential targets of
selected genes that are involved in the UPS and protein
degradation pathways that are linked to cell death.
The UPS is also known to play a role in the normal functioning
of synapses and defective proteolysis could cause the synaptic
dysfunction observed early in prion diseases [30–33]. Other
miRNA gene targets are also involved in the modulation of
synapse function including the neurotrophic factors, brain derived
neurotrophic factor (BDNF) and neurotrophin 3 (NT3) which
have crucial roles in the modulation of synaptic plasticity and in
maintenance of survival of neuronal populations [34,35]. Figure 3
shows an IPA generated network of 29 miRNA target genes that
have a high probability of interacting within neuronal synapses.
Genes coding for other factors involved in synapse function
including neurotransmitter receptors, gamma-aminobutyric acid
(GABA), glutamate receptors (GABRA1, GABRB2, GABRB3,
GRIA3, GRIA4) and SNAP25 are also potential targets of the up-
regulated miRNAs from the study. Expression of SNAP25 has
recently been shown to be down-regulated by miR-128 leading to
perturbation of neuronal activity [36]. We have previously shown
SNAP25 to be down regulated in scrapie infected mice, potentially
targeted by the up-regulated miR-128.
Enrichment of regulatory motifs in miRNA targets
Examination of the promoter regions of putative miRNA target
genes using the FatiGO tool revealed that regulatory motifs for a
small number of transcription factors including, E2F-1
(p=6.01610
214), KROX (p=9.34610
214), MAZ
(p=2.23610
211) and PAX6 (p=1.76610
29) are significantly
enriched in comparison to genes in the mouse genome as a whole
[37]. This suggests that the de-regulated miRNAs are involved in
co-ordinate regulation of networks of functionally related genes.
We have previously found the KROX family transcription factor
EGR1 to be differentially expressed in microarray studies of RNA
extracted from whole scrapie-infected brains [4]. MAZ is an
inflammation-responsive transcription factor that has been co-
localized to pathologic structures in Alzheimer’s disease brain
while up regulation of E2F1 has been shown to trigger cell cycle
re-entry of post-mitotic neurons leading to the initiation of
apoptosis in neurodegeneration associated with Parkinson’s disease
[38,39]. PAX6 has an important but complex role in neurogenesis
that is dependent on its expression level influencing cell
proliferation, differentiation and apoptosis [40–43]. EGR1 is itself
a putative target of two miRNAs identified in this study, miR-203
and miR-191. We used a luciferase reporter assay to determine
that miR-191, but not miR-203, is a potential regulator of EGR1,
Figure 4.
Comparative analysis of networks
The overlap between putative targets of miRNAs and the
expression of mRNAs provides information on the biological
functions and networks of genes regulated by specific miRNAs.
We used the IPA tool to identify linkages between putative targets
of de-regulated miRNAs and differentially expressed genes in
mouse scrapie [44,45]. The genes used in the comparison
comprised 349 prion related genes (PRGs) identified in a previous
study using in-house constructed microarrays consisting of cDNAs,
plus a further 684 genes identified using Agilent whole genome
mouse arrays [46]. In total, 119 (12%) of these genes are predicted
targets of de-regulated miRNAs by 2 or more miRNA target
prediction algorithms. This may be an inverse relationship, for
example, over-expressed miRNAs and down-regulated target
genes or down-regulated miRNAs and over-expressed target
Figure 1. Classification of prion disease-specific miRNA target genes into, A, functional groups and B, canonical pathways.
doi:10.1371/journal.pone.0003652.g001
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PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3652Figure 2. Functional relationships of miRNA target genes involved in the ubiquitin-proteasome pathway and unfolded-protein
response and cell death responses. This diagram shows the direct (solid lines) and indirect (dashed lines) interactions reported for these putative
target genes (grey shading) of miRNAs de-regulated in scrapie infection in mice. Biological network analysis was performed using Ingenuity Pathway
Analysis (IPA).
doi:10.1371/journal.pone.0003652.g002
miRNAs in Prion Disease
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instances, or indeed as activators of expression, a general
correlation in functionality of the two groups is of interest
[14,15]. The results of this analysis in terms of biological processes
and pathways into which miRNA targets and de-regulated genes
are correlated are provided in Figure 5. The closest linkages
between the data sets were found to be in the significant
enrichment for genes involved in cell death, regulation of the cell
cycle, nervous system development and function and cell signaling
pathways. Interestingly, the largest groups of de-regulated genes in
RNA from brains affected by prion disease are the inflammatory
response genes and these were not significantly represented
amongst the putative targets of the de-regulated miRNAs.
MiRNAs may be indirect regulators of these genes at the level
of transcription by regulation of transcription factors, given that
approximately a quarter of the putative targets of de-regulated
miRNAs are involved in this process. We determined that many of
these miRNA transcription related targets are potentially directly
involved in the expression of the 164 inflammation-related genes
de-regulated in mouse scrapie; a gene interaction network to
illustrate this is provided in Figure 6. These data suggest that
aberrant expression of miRNAs may modulate the activity of
particular transcription factors and alter gene regulatory circuits at
multiple hierarchical levels leading to the disease phenotype.
Figure 3. A network of 29 miRNA target genes that have a high probability of interacting within neuronal synapses.
doi:10.1371/journal.pone.0003652.g003
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This is the first report that comprehensively analyzes the brain
miRNA expression profile during prion-induced neurodegenera-
tion in mouse scrapie. Only a small number of miRNAs have so
far been associated with neurodegenerative processes: miR-133b,
miR-9, miR-125b, miR-132, miR-124a, miR-219 and miR-128
[19,20,47]. Of these, only miR-128 was significantly up-regulated
in the brains of scrapie infected mice. This miRNA has previously
been reported as increased in Alzheimer’s hippocampus [19].
Interestingly, we noted significant up-regulation of miR-342-3p
which is also one of three de-regulated miRNAs independently
identified in the brains of BSE-infected macaques (Dirk Motzkus,
German Primate Center, personal communication). A second
miRNA identified in this study, miR-26a, exhibited a trend
towards up-regulation in our study (.1.3 fold up-regulated in 5
out of 6 mice). The fact that we detected de-regulation of a unique
subset of miRNAs, but which are similarly expressed in different
models of TSEs, suggests a conserved, disease-specific pattern of
differentially expressed miRNAs is associated with prion–induced
neurodegeneration.
Recent studies in Dicer-deficient mice have highlighted the
importance of miRNAs in regulating neuronal function. In recent
studies the loss of Dicer in postmitotic Purkinje neurons and
midbrain dopamine neurons resulted in profound neurodegener-
ation resulting from cell death similar to that found in other
published Dicer loss studies [22,47]. However, in another study,
the ablation of Dicer in dopaminoceptive neurons resulted not in
cell death but led to neuronal dysfunction manifested by a range of
phenotypes including ataxia, front and hind limb clasping,
reduced brain size, and smaller neurons [48]. The pathways and
biological processes in which the miRNAs identified as deregulat-
ed in mouse scrapie participate are as yet unknown; only a handful
of publications explicitly relate to any of these specific miRNAs.
Linking a miRNA to its down-stream gene targets is a major
challenge in miRNA biology and only very few genes have been
experimentally confirmed as targets for specific miRNAs.
However, a variety of bioinformatic processes have been
developed which predict potential binding sites within the
sequence of gene 39 UTRs in an effort to identify genes regulated
by miRNAs. We used three of the leading algorithms to predict
gene targets for our list of disease-specific miRNAs and found that
transcriptional regulators, cell signaling molecules and genes
involved in cell death and neuronal development are strongly
represented amongst the potential targets. If mRNAs are altered in
prion disease then miRNAs targeting functionally related genes
Figure 4. MiRNA target gene validation of EGR1 using a luciferase reporter gene assay. A, Schematic representation of luciferase
constructs used for reporter assays. Specifically, EGR1 39UTR construct in pMIR-REPORT for transfection into HeLa cells. B, Dose dependent reduction
in the expression of luciferase activity when HeLa cells are co-transfected with miR-203 and C, co-transfection with miR-191.
doi:10.1371/journal.pone.0003652.g004
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case; analysis of these data showed extensive correlation between
the gene ontology assignments of de-regulated mRNAs, and
putative miRNA targets, in mouse scrapie infected brain,
strengthening the hypothesis of miRNA involvement in neurode-
generative disease processes.
Interestingly, some of the largest groups of de-regulated genes in
prion disease, for example inflammatory response-related genes
were not represented by the putative targets of de-regulated
miRNAs. The majority of miRNAs for which functions have been
determined appear to exert their effects by down-regulation of
specific targets. MiRNAs may be indirect regulators of immune
response genes at the level of transcription control. A number of
such instances have been described for the regulation of genes
involved in transcription by miRNAs as part of a feed back loop.
One interesting example is the indirect regulation of the
neurotrophic factor BDNF by miR-132 [49]. In this case, miR-
132 regulates the translation of transcriptional co-repressor methyl
CpG–binding protein 2 (MeCP2), the levels of which are under
tight regulation in the brain as both increases and decreases in it
expression have been shown to result in neurodevelopmental
defects. Additionally mutations in MeCP2 have been linked to the
neurodevelopment disorder Rett syndrome underlining its impor-
tance. BDNF expression is modulated by MeCP2 as part of a feed-
back loop in which miR-132 plays a role, perhaps along with other
miRNAs. We identified the up-regulation of miR-328, which also
potentially targets MeCP2, perhaps implicating the disruption of
neurodevelopmental regulatory circuits is a feature of prion
disease.
Given the strong inverse correlation between up-regulated
miRNAs and the down regulation of behaviour-related genes,
particularly those involved in synaptic function, we investigated
the possibility of miRNA mediated regulation of these genes. One
gene of interest to us was the transcriptional regulator EGR1. This
gene has been shown by us to be consistently down-regulated in
scrapie infected mouse brain, detectable at pre-clinical stages of
disease [4]. In this study we show that at least in vitro, the 39UTR is
a target site of miRNA miR-191, which is up-regulated during
scrapie infection. EGR1 has been shown to share a dispropor-
tionate number of transcriptional targets with CREB1, also down-
regulated in prion disease, suggesting that these two may be
functionally related. They have also both been shown to be
activated in conjunction with neural activity and indeed disruption
of CREB1 expression has been shown to result in hippocampus
neurodegeneration [38]. Analysis of the 39 UTR sequence of
CREB1 showed that it shares a number of potential target sites for
Figure 5. Comparison of the GO assignments for putative target genes of differentially expressed miRNAs with genes identified to
be differentially regulated in prion diseases. A, De-regulated target genes that show a correlation with de-regulated prion related genes. B,
Functionally-related genes that are strongly de-regulated in mouse scrapie but have little or no representation among putative target genes of
miRNAs that exhibit differential expression in prion disease (solid bars, genes de-regulated in mouse scrapie, hatched bars, putative targets of de-
regulated miRNAs).
doi:10.1371/journal.pone.0003652.g005
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PLoS ONE | www.plosone.org 7 November 2008 | Volume 3 | Issue 11 | e3652miRNAs with EGR1. Interestingly, CREB1 has also been shown
to be involved in regulation of expression of a number of miRNAs
and may be intimately involved in regulatory networks mediating
neuronal function and morphogenesis [49–53].
In conclusion, we have identified a number of miRNAs that
appear to be de-regulated during prion induced neurodegenera-
tion. A number of genes and signaling pathways important in
neuronal degeneration in prion diseases are likely regulated at least
in part by miRNAs. A co-ordinated de-regulation of miRNAs seen
in prion diseases may well be a response to the abnormal
accumulation of PrP
Sc leading to a pathogenic cascade consisting
of compensatory alterations in neurotransmitter receptors, protein
degradation pathways and signaling pathways which lead to an
ultimate failure of neuronal function. Many miRNAs have been
found to show tissue and cell specific expression; it will be
interesting to determine the cell types in which the de-regulated
Figure 6. Functional relationships of de-regulated immune response-related genes in the brains of mice infected with scrapie and
the putative transcription regulator genes that are targets of miRNAs similarly de-regulated. This biological network illustrates the
potential for indirect regulation of immune-response related genes by miRNAs via modulation of transcriptional regulators. Nodes colored in red
denote up-regulated genes in mouse scrapie whereas green denotes down-regulated genes. Nodes with an orange border denote the putative
targets of miRNAs deregulated in mouse scrapie.
doi:10.1371/journal.pone.0003652.g006
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regulatory pathways that lead to cell death in neurons. Given the
ability of miRNAs to target multiple genes for expression, and
their potential for modulating neuroprotective mechanisms, the
prospect of using miRNAs as therapeutics in neurodegenerative
diseases is tantalizing. MiRNAs may also have potential for use as
biomarkers given our evidence of de-regulation of a prion-specific
subset of miRNAs that is distinct from other neurodegenerative
diseases and potentially conserved across species.
Materials and Methods
Animals
All procedures involving live animals were approved by the
Canadian Science Centre for Human and Animal Health Animal
Care Committee. All protocols were designed to minimize animal
discomfort. Inoculations were performed as previously described [4].
MicroRNA extraction
MiRNAs were extracted using the mirVana
TM miRNA Isolation
Kit (Ambion) according to the manufacturer’s instructions. This
procedure yields an RNA fraction consisting of RNA species of less
than 200 bases. Yield and purity of the miRNA enriched fraction
was measured by UV absorbance at OD260/280.
MicroRNA microarray procedures
MiRNA microarrays were performed as previously described [23].
Specifically, the Array 900 miRNA RT Kit (Genisphere) was used to
prepare labeled cDNA targets for microarray hybridization accord-
ing to the manufacturer’s protocol. Briefly, 250 ng of LMW enriched
RNA was used as a template in a 100 mLP o l y ( A )T a i l i n ga n dR T
reaction containing 16Reaction Mix, 2.5 mM MnCl2,1m MA T P ,
and 4 mLp o l yAp o l y m e r a s e( E-PAP Enzyme). After incubation at
37uC for 15 minutes the reaction was placed on ice and 2 mLo fC y 3
or Cy5 reverse transcriptase primer was added. The reaction mix was
incubated at 65uC for 10 minutes prior to addition of 23 mLo fa
second master mix containing per reaction: 10 mLo f5 6First Strand
Buffer, 5 mL of 0.1 M DTT, 2.5 mLo fd N T PM ix ,1mLofSuperase-
in RNase Inhibitor, 2 mL of SuperScript II Reverse Transcriptase
(200 U) (Invitrogen), and 2.5 mL of nuclease-free water. Subsequent-
ly, the reaction was incubated at 42uC for one hour. Finally, 8.75 mL
of 0.5 M NaOH/50 mM EDTA and 65uC for 15 minutes was used
to inactivate Superscript II. Samples were concentrated to a volume
of approximately 10–15 mL, using Microcon YM-10 Centrifugal
Filter Devices (Fisher Scientific) according to the manufacturer’s
protocol.
Tagged-cDNA hybridization followed the protocol outlined in
the 900 miRNA RT Kit. A hybridization mixture consisting of the
differentially tagged cDNA (10 mL of Cy3-labelled and 10 mLo f
Cy5-labelled targets) and 26SDS-based Hybridization Buffer pre-
heated to 70uC (20 mL) was mixed and incubated at 75–80uC for
10 minutes, cooled to 50uC until loading and added to the
microarray; specifically a 22640 mm cover slip (mSeries Lifter-
slip
TM) (Erie Scientific) was centered over the grids and the
preheated hybridization mixture was loaded under the cover slip.
Microarrays were incubated overnight (16–20 hours) at 50uCi na
dark humidified chamber (Genetix). Following hybridization the
cover-slips were removed and the arrays were washed in 26SSC,
0.2% SDS wash buffer preheated to 42uC for 15 minutes, 26SSC
wash buffer at room temperature for 10–15 minutes, and
0.26SSC wash buffer at room temperature for 10–15 minutes.
Arrays were dried by centrifugation at 1000 rpm for 2–3 minutes
and the 3DNA system containing the fluorescent cyanine
molecules were hybridized to the arrays; in this case the
hybridization mixture contained Cy3 3DNA Capture Reagent
(2.5 mL), Cy5 3DNA Capture Reagent (2.5 mL), Nuclease Free
Water (15 mL), and 26SDS-based Hybridization Buffer. The mix
was heated to 70uC for 10 minutes, cooled to 62–64uC and
hybridized to the arrays for 4 hours at 62–64uC in a dark
humidified chamber. Finally, the arrays were washed as previously
described [23].
Microarrays were scanned using Agilent G2565AA and Agilent
G2565BA Microarray Scanner System (Agilent). Feature extrac-
tion was performed using Array-Pro
TM analyzer version 4.5
(Media Cybernetics). Data was Log2 transformed and normalized
using Lowess subgrid normalization in GeneTraffic Microarray
Database and Analysis System (Iobion Informatics). The miRNA
microarray related data were submitted to Gene Expression
Omnibus (GEO) under accession numbers: [GSE12354].
Significance Analysis of Microarrays (SAM)
To identify miRNAs that were most significantly different in
expression between the scrapie infected mice and age-matched,
mock-infected mice, a one-class SAM analysis [54] with a false
discoveryrate(FDR)of,20%was used.Toincreasetheconfidence
level of our results, the only miRNAs selected were those with: (1)
minimum intensity levels above that of negative control miRNAs
spotted on the array, (2) signal-to-background ratio $1.5 and (3)
readings for $50% of the data points was present.
Quantitative RT-PCR (TaqManH MiRNA Assays)
Reverse transcriptase reactions were performed using the
TaqManH MicroRNA Reverse Transcription Kit (Applied Biosys-
tems). Each reaction contained 20 ng LMW enriched RNA, 1 mM
dNTPs (with dTTP), 1 mL of 3.3 U MultiScribe
TM Reverse
Transcriptase, 16 Reverse Transcription Buffer, 3.75 U RNase
Inhibitor, and 3 mL of RT primer. The reaction was carried out at
16uC for 30 minutes, 42uC for 30 minutes, and 85uC for 5 minutes.
Semi-quantitative PCR reactions were performed according to the
methodology outlined in the TaqManH MiRNA Assay Kit (Applied
Biosystems).Briefly,eachreactioncontainedTaqMan16Universal
PCR Master Mix (No AmpErase UNG), 16TaqManH MicroRNA
Assay Mix, and 1.33 mL of the RT product in a total volume of
20 mL. Each reaction was incubated in an Applied Biosystems 7500
Real Time PCR System in a 96-well plate at 95uC for 10 minutes,
followed by 40 cycles of 95uC for 15 sec and 60uC for 1 minute.
The threshold cycle (Ct) method was used to determine the relative
quantities of each miRNA, and was defined as the fractional cycle
number at which the fluorescence passes the fixed threshold. Target
miRNA expression was normalized between different samples based
on the values determined for let-7a miRNA expression which was
found to beroutinelyconsistently expressed inallofthesamplestested
at the same Ct value (no differential expression between samples). All
samples were tested in triplicate throughout. Expression was
calculated using the DDCt method: 2
DCt Scrapie-infected2DCt mock-infected
with DCt=average Ct target miRNA – average Ct let-7a. MiR-16
w a su s e da st h ep o s i t i v eco n t r o l sa n dC.elegans and A.thaliana miRNAs
were used as the negative controls in the experiment.
MiRNA reporter vector constructs, transfection and dual
luciferase reporter assays
To create EGR1 39UTR luciferase reporter constructs, a
,1200 bp fragment of the 39UTR (bp 1885-3072 of
NC_000084.5) was cloned downstream of CMV-driven firefly
luciferase cassette in pMIR-REPORT vector (Ambion). The
39UTR of EGR1 was cloned from total mouse cDNA using
forward primer 59 gtacactagtagggaataaaagaaagcaaagggag 39 and
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PLoS ONE | www.plosone.org 9 November 2008 | Volume 3 | Issue 11 | e3652reverse primer 59 gtacaagcttgaaggatacacaccacata 39 (Operon
Biotechnologies). The FastStart Taq Polymerase PCR kit (Roche)
was used to amplify the 39UTR target sequence. Following
purification of PCR products using Kleenspin (Biorad), the
amplicon and pMIR-REPORT were digested with SpeI and
HindIII restriction enzymes (NEB) at 37uC for 1 hr. Further
purification was performed and the products were then ligated at
16uC overnight. Ligation products (2 mL) were then used to
chemically transform One Shot TOP10 E.coli cells (Invitrogen).
Transformed culture (100 mL) was plated on 100 mg/mL LB
carbenicillin agar plates and the resulting colonies were screened
for the EGR1 insert using the HotStar HiFidelity Polymerase Kit
(Qiagen). Selected positive clones were propagated in 100 mg/mL
LB agar at 37uC for 24 hrs and the plasmid was extracted using
the EndoFree Plasmid MaxiPrep kit (Qiagen). Subcloned inserts
were sequenced by the DNA core facility at the National
Microbiology Laboratory at the Canadian Science Center for
Human and Animal Health and verified by BLASTN search.
The pMIR-REPORT
TM miRNA Expression Reporter Vector
(Ambion) was used to analyze putative miRNA target binding sites
in combination with the Dual-Light Chemiluminescent Reporter
Gene Assay System (Applied Biosystems). The siPORT
TM
NeoFX
TM TransfectionAgent kit (Ambion) was used to co-transfect
HeLa cells with both the reporter vector and mmu-miR-203 or
mmu-miR-191 (Ambion). A b-galactosidase reporter control vector
was also co-transfected in parallel with the EGR1 vector for
normalization of transfection efficiencies. Briefly, 300 ng of the
reporter vector and 300 ng of the control vector were diluted in
OPTI-MEM media (GIBCO) containing 15, 30, 60 or 100 nM of
the synthetic mature miRNA of interest in a final volume of 100 ml.
Concurrently, a 6:100 dilution of the transfection reagent was made
in OPTI-MEM and pre-incubated for 10 min at 37uC. Subse-
quently, 100 ml of the diluted transfection reagent and 100 mLo f
the reporter plasmid/miRNA dilution were left at room temper-
ature for an additional 10 min. The 200 mL samples were mixed
with 2.3 mL of DMEM (GIBCO) containing 2.5610
5 Hela cells/
mL and then plated in 6-well plates and incubated for an additional
24 hr at 37uC prior to assaying for luciferase activity.
The chemiluminescent reporter gene assay was used for the
combined detection of luciferase and b-galactosidase activities
according to the manufactures instructions. Luciferase activity was
measured using the dual injecting Veritas
TM Microplate Lumi-
nometer (dual injecting) (Turner Biosystems). Each experimental
condition was performed in triplicate or quadruplicate within
individual experiments and the results shown represent at least
three independent experiments. All results were normalized using
simultaneously measured b-galactosidase activity.
MicroRNA Target prediction
To determine the gene targets of the differentially expressed
miRNAs we used three of the leading miRNA target prediction
algorithms miRanada (http://microrna.sanger.ac.uk/sequences/)
[26], PicTar (http://pictar.mdc-berlin.de/) [27], TargetScan
(http://www.targetscan.org/) [28]. To determine genes that were
similarly identified by two or more of these algorithms, the online
program Matchminer (http://discover.nci.nih.gov/matchminer/
index.jsp) was used [55].
Functional Analysis of MiRNA Target Genes
Functional analysis of MiRNA Target Genes was performed using
Ingenuity Pathways Analysis (IngenuityH Systems). This software
analyses lists genes in the context of known biological response and
regulatory networks as well as other higher-order response pathways.
MiRNA targets that were associated with biological functions in the
Ingenuity Pathways Knowledge Base were used in the analysis (focus
genes). For all analyses, Fisher’s exact test was used to calculate a p-
value determining the probability that each biological function
assigned to that data set was due to chance alone. Networks of the
focus genes were then algorithmically generated based on their
connectivity. In the functional network shown in figures 2 and 3,
miRNA target genes are represented as nodes, and the biological
relationship between two nodes is represented as an edge (line). All
edges are supported by at least one published reference or from
canonical information. Enrichment of transcription factor motifs in
putativemiRNAtargetgeneswasperformed usingFatiGO [37]. This
tool uses information collected on regulatory motifs from the CisRed
[56] and TRANSFAC [57] databases. These motifs were studied in
the first 5 Kb of the promoter sequence as described in Al-Sharouf et
al. [37].
Supporting Information
Data S1 DDCT for 114 miRNAs detectable in mouse brain 6
mice infected with scrapie.
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Data S2 List of 1282 miRNA target genes that were in
consensus between two or more miRNA target prediction
programs.
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